# AbbVie Inc. (ABBV)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/ABBV/primer

## Business Model

---
ticker: ABBV
step: 01
generated: 2026-05-11
source: quick-research
---

### AbbVie Inc. (ABBV) — Business Overview

#### Business Description
AbbVie is a global research-based biopharmaceutical company spun off from Abbott Laboratories in 2013. Its business is anchored by immunology (Skyrizi + Rinvoq + Humira), with sizable franchises in neuroscience, oncology, aesthetics (Allergan's Botox + Juvederm), and eye care. After successfully navigating the largest patent cliff in pharma history (Humira, peak $21.2B sales in 2022), AbbVie's combined Skyrizi + Rinvoq sales exceeded $25B in 2025 and are tracking to >$31B by 2027 — already surpassing peak Humira.

#### Revenue Model
- **Immunology (~45% of revenue):** Skyrizi (IL-23), Rinvoq (JAK), residual Humira (TNF) — fast-growing replacements offsetting Humira biosimilar erosion
- **Oncology (~10%):** Imbruvica (BTK, partnered with J&J), Venclexta, Epkinly, Elahere
- **Neuroscience (~14%):** Vraylar, Botox Therapeutic, Ubrelvy, Qulipta — growing 17%+ annually
- **Aesthetics (~9%):** Botox Cosmetic, Juvederm, CoolSculpting (acquired via Allergan 2020)
- **Eye Care (~6%):** Restasis, Xen, Vuity (presbyopia)
- **Other (~16%):** Mavyret (HCV), Creon, Hytrin

#### Products & Services
- **Skyrizi (risankizumab):** IL-23 inhibitor for psoriasis, psoriatic arthritis, Crohn's, ulcerative colitis — $17.6B in 2025 ($21.5B 2026E)
- **Rinvoq (upadacitinib):** JAK1 inhibitor for RA, psoriatic arthritis, atopic dermatitis, IBD, vitiligo (filed) — $8.3B in 2025 ($10.1B 2026E)
- **Humira (adalimumab):** Legacy TNF inhibitor, now ~$2.9B/year and shrinking ~40% annually post-LOE
- **Botox / Juvederm:** Aesthetics franchise from $63B Allergan acquisition (2020)
- **Vraylar:** Atypical antipsychotic for bipolar, depression
- **Vylept:** New Parkinson's drug (FDA approved 2026)
- **Pipeline:** Tirvapadone (Parkinson's, Phase 3), Entantamig (multiple myeloma, Phase 3), Crohn's combo platform

#### Customer Base & Go-to-Market
- **Patients:** Millions globally, often with chronic disease (autoimmune, oncology)
- **Prescribers:** Specialist physicians (rheumatology, dermatology, gastroenterology, neurology, oncology)
- **Payers:** US PBMs/insurers, ex-US single-payer systems negotiate aggressively
- **Aesthetics channel:** Direct to dermatologists and plastic surgeons; consumer awareness via DTC marketing
- Geographic mix: ~75% US revenue, ~25% International

#### Competitive Position
AbbVie has the most successful biopharma post-LOE transition on record — Skyrizi and Rinvoq combined have already surpassed peak Humira. Moats include (1) strong specialty sales force relationships in immunology, (2) scientifically differentiated mechanisms (IL-23 + JAK selective JAK1), (3) Allergan aesthetics distribution franchise, and (4) capital allocation discipline using free cash flow for tuck-in M&A (ImmunoGen, Cerevel) to refresh pipeline. Competes with J&J (Stelara, Tremfya), Eli Lilly (Olumiant, Omvoh), Bristol-Myers (Sotyktu), Pfizer (Xeljanz), Roche (Vabysmo) across therapy areas.

#### Key Facts
- Founded: 2013 (spin off from Abbott Labs)
- Headquarters: North Chicago, IL
- Employees: ~55,000
- Exchange: NYSE
- Sector / Industry: Health Care / Pharmaceuticals
- Market Cap: ~$365B (May 2026)
- CEO: Rob Michael (succeeded Richard Gonzalez 2024)
- Dividend: ~$6.59 annual; 52+ consecutive years (counting Abbott history) — Dividend King via predecessor lineage

## Financial Snapshot

---
ticker: ABBV
step: 04
generated: 2026-05-11
source: quick-research
---

### AbbVie Inc. (ABBV) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2023 | FY2024 | FY2025 | YoY |
|--------|--------|--------|--------|-----|
| Revenue | $54.3B | $56.3B | $61.2B | +8.6% |
| Adj. Gross Margin | 84% | 84% | 84% | flat |
| Adj. Operating Margin | 47% | 46% | 47% | +1pp |
| Adj. Net Income | $21.5B | $20.5B | $22.4B | +9% |
| Adj. EPS (diluted) | $11.11 | $10.61 | $12.20 | +15% |

#### Product Sales (FY2025 vs FY2024)

| Drug | FY2024 | FY2025 | YoY |
|------|--------|--------|-----|
| Skyrizi | $11.7B | $17.6B | +50% |
| Rinvoq | $6.0B | $8.3B | +39% |
| Humira | $9.0B | $5.5B | -39% |
| Skyrizi + Rinvoq combined | $17.7B | $25.9B | +46% |
| Total Immunology | ~$27B | ~$32B | +18% |
| Imbruvica | $3.1B | $2.9B | -7% |
| Vraylar (neuroscience) | $3.0B | $3.5B | +17% |
| Botox Cosmetic | $2.7B | $2.8B | +4% |

#### Q1 2026 Highlights

| Metric | Q1 2026 | YoY |
|--------|---------|-----|
| Total Revenue | ~$13.5B | +12.4% |
| Skyrizi | $4.48B | +30.9% |
| Rinvoq | ~$2.4B | +20% |
| Humira | $688M | -39% |

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$22B |
| Capital Expenditures | ~($1.0B) |
| Free Cash Flow | ~$21B |
| Cash & Equivalents | ~$5B |
| Total Debt | ~$67B (post Allergan/ImmunoGen/Cerevel) |
| Net Debt / EBITDA | ~2.0x (declining) |

#### Key Ratios (approximate, May 2026)
- P/E (forward): ~14x | EV/EBITDA: ~13x | Dividend Yield: ~3.2%
- ROIC: ~14% | FCF/Net Income conversion: ~95%

#### Growth Profile
2025 was the inflection year: total revenue +8.6%, with Skyrizi (+50%) and Rinvoq (+39%) more than offsetting Humira (-39%). Management guides 2026 revenue to $67B (+9.5%) and EPS to $14.37-14.57. Combined Skyrizi+Rinvoq guidance raised to >$31B by 2027 (vs. prior $27B), implying 19% organic CAGR despite Humira running off to ~$2B/year. Aesthetics segment softening (consumer discretionary headwind) but immunology + neuroscience more than offsetting.

#### Forward Estimates
- **2026E Revenue:** $67B (mgmt guide; +9.5%)
- **2026E Adj EPS:** $14.37-14.57 (mgmt guide)
- **2027E Revenue:** ~$73B (consensus)
- **2027E Adj EPS:** ~$16
- **Skyrizi 2027 target:** >$20B (raised from $17B)
- **Rinvoq 2027 target:** >$11B (raised from $10B)

#### Capital Return
- Dividend $6.59/share annual = ~$11.5B paid
- 52+ years of consecutive dividend growth (counting Abbott predecessor)
- Modest buybacks (~$2B/year) given priority on debt paydown post-Allergan
- Total return: ~3.2% dividend yield + buybacks + 9%+ FCF growth

## Recent Catalysts

---
ticker: ABBV
step: 12
generated: 2026-05-11
source: quick-research
---

### AbbVie Inc. (ABBV) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Skyrizi + Rinvoq exceeding peak Humira already** — Combined 2025 sales of $25.9B already exceed Humira's $21.2B 2022 peak. Q1 2026: Skyrizi +30.9% to $4.48B, Rinvoq +20%. Mgmt raised 2027 combined target to >$31B (from prior $27B). The IL-23 + JAK-selective combo is winning indication after indication — psoriasis, PsA, Crohn's, UC, atopic dermatitis, vitiligo (filed). This proves the post-Humira transition is *more successful* than original guidance suggested.

2. **2026 inflection: 9.5% revenue growth, EPS $14.37-14.57** — Management's 2026 guidance demonstrates the company has decisively cleared the Humira biosimilar headwind. With Humira now <$3B/year and shrinking ~40% annually (stable run-rate $1-2B by 2027), every dollar of Skyrizi/Rinvoq growth drops to revenue. Operating leverage from immunology growth + cost discipline pushes Adj OM toward 48-49%.

3. **Neuroscience as the next growth pillar** — Vraylar (+17%) is a $3.5B drug growing as a leading bipolar/depression treatment. Cerevel acquisition added tirvapadone (Parkinson's, Phase 3) and emraclidine. Vylept (FDA approved 2026) adds another Parkinson's asset. Phase 3 success for tirvapadone could add $2B+ annually.

4. **3.2% dividend yield + 52-year track record** — AbbVie inherits the Abbott dividend lineage; combined the family has paid an increasing dividend for 52+ consecutive years. The dividend is well covered with FCF ($21B FCF vs $11.5B dividend). Combined with 14x forward P/E, this is a "GARP + yield" stock in a sector facing political headline risk.

#### Bear Case Risks

1. **Humira erosion accelerating + Imbruvica IRA pricing** — Humira -39% YoY in Q1 2026 to $688M with continued biosimilar share losses. Imbruvica (J&J-partnered) faces IRA Medicare price negotiations — sales guided to $2.2B in 2026 (-23%). Combined Humira + Imbruvica headwind is ~$1.5B/year drag on growth.

2. **Skyrizi/Rinvoq LOE eventually** — Skyrizi US LOE ~2032; Rinvoq US LOE ~2034. While distant, biopharma multiples typically compress 4-5 years pre-LOE. The current bull thesis assumes pipeline (Cerevel/ImmunoGen acquisitions, Crohn's combo, AbbVie internal R&D) successfully covers a second cliff. Failure to land another 3-4 blockbusters by 2028 risks repeating the patent cliff cycle.

3. **Aesthetics weakness** — Botox Cosmetic and Juvederm growth slowing (+4% in 2024) as discretionary consumer spending softens and GLP-1 weight-loss users reportedly need less facial filler. Q4 2025 commentary highlighted aesthetics softness; this previously high-margin segment provides less offset to other categories.

4. **Debt + M&A discipline test** — $67B total debt post-Allergan/Cerevel/ImmunoGen is large. Management has prioritized deleveraging but the pace depends on FCF stability. If immunology pricing pressure increases (IRA Part D negotiations, EU price referrals), the deleveraging pace slows, constraining further pipeline-refresh M&A.

#### Upcoming Events

- **Q2 2026 earnings (late July)** — Skyrizi/Rinvoq trajectory; Humira run-rate visibility
- **Q3 2026 earnings (October)** — Vitiligo Rinvoq approval / launch trajectory
- **Tirvapadone Phase 3 readout** — Late 2026 / Early 2027 — Parkinson's data could de-risk pipeline
- **Crohn's combo data** — Skyrizi + Rinvoq combo for severe IBD — pivotal data through 2026-27
- **Entantamig (multiple myeloma) Phase 3** — Potential 2026-27 readout

#### Analyst Sentiment

Sell-side consensus is **Buy / Strong Buy** with average price targets in the $230-250 range vs. recent ~$203 trading levels (~13-23% upside). Bulls cite the proven post-Humira transition, 9.5% guided revenue growth, 14x P/E, and 3.2% dividend. Bears focus on the eventual Skyrizi/Rinvoq LOE, Imbruvica IRA decline, and aesthetics weakness. Net consensus is positive but multiple compression at LOE remains a long-term overhang.

#### Research Date
Generated: 2026-05-11

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/abbv
- Full research API: GET /api/v1/research/ABBV/memo
- Coverage universe: /stocks